יחס מחיר לרווח G1 Therapeutics Inc. (GTHX)

G1 Therapeutics - לוגו גרפי של המנפיק GTHX

G1 Therapeutics, Inc. (GTHX) relies on outsourcing for production and testing, maintaining the mobility of its scientific staff without incurring unnecessary costs. The key catalyst was the $405 million acquisition of Pharmacosmos to secure the rights to Cosela. Serving as the primary valuation tool, this price chart, where the metric stands at -8.50, illustrates the conclusion of the public phase and the merger with a pharma behemoth to scale sales of the bone marrow protection agent.

G1 Therapeutics Inc. (GTHX) - יחס מחיר לרווח מ-04.07.2022 עד 28.09.2024

פילוחי מדדים מקיפים ואנליטיקה עבור g1therapeutics.com (GTHX)

- מחיר ותחזית קונצנזוס למחירים:
ניתוח מקיף של החברה:GTHX (G1 Therapeutics Inc.)
דוגמת מוצר של G1 Therapeutics, Inc.

The P/E ratio determines the cost of one dollar of net profit, reflecting market expectations for future growth. By analyzing the current price-to-earnings valuation, an investor sees the balance between capitalization and actual income. The multiplier's dynamics react instantly to changes in financial results and shareholder sentiment. For G1 Therapeutics, Inc. (GTHX), this indicator accounts for drug development risks. Licensing rights in Europe and Asia stabilize profits, reducing valuation volatility.